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ABSTRACT

Molecular Studies Involving the Rev Proteins of Caprine Arthritis Encephalitis Virus and Visna
Virus
by
Bridget M. Graves
Caprine Arthirtis Encephalitis Virus (CAEV) and Visna Virus are two viruses of the lentivirus
family. They encode three structural genes (gag, pol, and env) and two regulatory genes (rev and
tat). The Rev protein regulates Gag, Pol, and Env expression by transporting their mRNAs to
the cytoplasm by binding to the RRE (Rev Response Element) found on their mRNAs. Previous
studies have indicated that Rev may be toxic to transfected cells, overexpression of exogenous
RREs or a better binding RRE can inhibit Rev activity and Rev-C (CAEV Rev) can transactivate RRE-V (Visna Virus RRE). To test these possibilities FACS analysis, RNA binding
assays, cotransfections, and SELEX were done. The results indicated that Rev is not acutely
toxic to cells, inhibition of Rev activity could not be achieved by making a better binder or
through expression of exogenous RREs, and Rev-C can trans-activate RRE-V implicating
conservation of Rev/RRE interactions in lentiviruses.
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CHAPTER 1
INTRODUCTION

Lentiviruses are complex, non-oncogenic retroviruses known for their “slow” progression
of disease (Joag et al. 1996, Pollard and Malim 1998). The most well known lentivirus is the
Human Immunodeficiency Virus type 1 (HIV-1) that infects humans and causes Acquired
Immunodeficiency Syndrome (AIDS) by replicating in and destroying both lymphocytes and
macrophages (Luciw 1996, Clements and Zink 1996). The resulting immunological disease
leads to opportunistic infections, neurologic disorders, unusual forms of cancer, and eventually
death (Luciw 1996). Caprine Arthritis-Encephalitis Virus (CAEV), which infects goats, and
Visna Virus, which infects sheep, are also lentiviruses but their course of disease is different
from that of HIV-1. CAEV and Visna Virus generally are more organ specific in their pathology
and replicate predominately in macrophages (Clements and Zink 1996, Joag et al. 1996). While
Lentiviruses may differ in their tissue tropism, they do share similar genetic compositions and
can therefore be studied generally as one virus. Any drug or vaccine discovered for one virus is
likely to be applicable to all lentiviruses.
Lentiviral Disease and Pathology
Two characteristics of Lentiviral infections important for their progression of disease is
persistence in the face of host immune responses and antigenic variation (Blacklaws et al. 1995,
Clements and Zink 1996, Joag et al. 1996). Lentiviruses are able to persist in the host by
integrating into their host’s genome. In doing so, their host is never able to completely clear the
virus (Joag et al. 1996). The antigenic variation characteristic of Lentiviruses is a result of a
defect in their replicative machinery. Lentiviruses use reverse transcriptase, an error prone
enzyme, to replicate. This results in a high number of mutations and a continuous changing of
antigenic markers for the infecting virus, thereby allowing the virus to evade the host immune
response (ibid). The use of antiviral drugs against lentiviral infections has also led to variation of
9

the viruses as they mutate to drug resistance as a result of drug therapy (Joag et al. 1996, Luciw
1996).
Lentiviral infections typically progress through a specific pattern of phases as shown in
Figure 1 (Joag et al. 1996). After initial infection, there is intense productive viral replication in
lymphocytes and/or macrophages along with immunologic activation of the cells that distribute
virus throughout the body (ibid). This is known as the acute phase of infection. The next phase
involves the host’s antiviral immune response that leads to a reduction of viral replication, but an
incomplete clearing of the virus from the system. This is known as the clinical latency phase.
During this time, which lasts for months to years, the virus continues to replicate in virally
disseminated organs and tissues. The late phase of viral infection involves a resurgence of viral
replication due to the faltering of the exhausted and/or compromised host’s immune system.
This leads to symptoms of disease and eventually death of the host.
Lentiviruses primarily infect and replicate in macrophages and lymphocytes which are
terminally differentiated, non-dividing immune cells. Lentiviruses can be classified into two
groups based on their cell tropism. HIV, Feline Immunodeficiency Virus (FIV), and Simian
Immunodeficiency Virus (SIV) are examples of Lentiviruses that can replicate in both
lymphocytes and macrophages. These viruses cause both immunodeficiency disease and organ
specific inflammatory disease. In contrast, the Lentiviruses CAEV and Visna Virus replicate
mainly in macrophages and they cause only organ specific disease. The cell tropism is the
primary reason for the differences in disease caused by the two groups (Clements and Zink 1996,
Joag et al. 1996).
Goats infected with CAEV can develop arthritis, encephalitis, and mastitis. Vertical
transmission of CAEV via colostrum between dam and kid is the main mode of transmission
between goats. However, horizontal transmission (animal to animal) of CAEV is on the rise
(Clements and Zink 1996). Sheep infected with Visna Virus can develop chronic pneumonia and
a neurologic condition characterized by wasting and paralysis. There currently is no effective
10

treatment or vaccine available to treat lentiviral diseases. Because the viruses will eventually kill
the infected animals, infected animals are culled in an effort to control the spread of infection
among herds. Understandably, this is a costly method of control and it has a severe impact on
the agricultural industry yearly. Therefore, any effective treatment or vaccine that can be
developed would save millions in lost animals yearly worldwide.

Figure 1. Typical Course of a Lentivirus Infection. Reprinted from Jawetz, Melnick and
Adelberg’s Medical Microbiology, 20th ed., Appleton and Lange Publishers, 1995.
Lentiviral Structure and Genomic Organization
Lentiviruses are a subfamily of retroviruses that have a complex genome and structure.
Figure 2 shows a diagram of the HIV-1 structure which can serve as the model for all
11

lentiviruses. The lipid bilayer membrane contains the envelope glycoproteins gp120 and gp41,
which bind to the host CD4+ cells. The gag matrix protein (MA) surrounds the gag capsid
protein (CA) that encircles the nucleocapsid protein, integrase, reverse transcriptase, protease,
and other viral enzymes. The gag nucleocapsid (NC) protein surrounds the two single stranded
RNA copies of the viral genome.

Figure 2. Lentivirus Structure (Reprinted from Field’s Virology, Vol. 2, Lippincott-Raven
Publishers, p. 1886). This Figure of HIV-1 is representative of the general features of all
lentiviruses.

The amino acid sequences of CAEV and Visna Virus have moderate homology with each
other as seen in Figure 3. As one might expect, they have essentially the same genomic
organization as demonstrated in Figure 4 (Joag et al. 1996, Luciw 1996). They have three
structural genes known as gag, pol, and env. The gag gene encodes the capsid, nucleocapsid,
and core proteins. The pol gene encodes the viral enzymes protease, reverse transcriptase,
RNase H, integrase, and dUTPase. Protease is responsible for cleaving the core proteins into
12

their final forms. Reverse transcriptase is responsible for synthesizing the single stranded RNA
template into DNA. RnaseH functions by degrading the RNA from the RNA/DNA hybrids
made during reverse transcription. Integrase is responsible for integration of the double stranded
DNA viral genome into the host cell DNA. The enzyme dUTPase helps to maintain a low ratio
of dUTP to dTTP in the host cell and thus minimizing the incorporation of uracil into DNA
(Turelli et al. 1996, Turelli et al. 1997, Pe′tursson et al. 1998). The env gene encodes the
envelope glycoproteins gp42 and gp135 that are responsible for binding of the virion to the host
cell receptors.

CAEV Co
VMV SA-OMVV
VMV KV1514
VMV KV1772
1% difference

Figure 3. Phylogenetic Relationship Between Strains of CAEV and Visna Virus. The genomic
sequences of the CAEV Cork strain (CAEV Co), Visna Virus strains 1514 (VMV KV1514),
1772 (VMV KV1772) and SA-OMVV (South African Visna Virus strain) were compared using
the Neighbor Joining Method of Saitou and Hei using Vector NTI, Suite 6.0 (InforMax Corp.).
The horizontal distance indicates the degree of relatedness between the sequences.
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RRE

Env
5’LTR

Tat

Pol
Gag

Vif

Rev

3’LTR

Figure 4. CAEV and Visna Virus Genomic Organization. The stacked boxes represent the three
Open Reading Frames (ORF’s). The structural genes are gag, pol, and env. The three regulatory
genes are vif, tat, and rev. Rev is encoded in the env open reading frame and the Rev Response
Element (RRE) is located in the env ORF. LTR refers to Long Terminal Repeats.

At the ends of the CAEV and Visna Virus genomes are two long terminal repeats (LTRs).
They are involved in the integration into the host cell genome and also contain signals for
transcriptional activation, RNA synthesis, capping, and polyadenylation. There is one accessory
gene called vif (viral infectivity factor) that facilitates spread of the virus (Clements and Zink
1996). There are also two regulatory genes called tat and rev that are absolutely necessary for
productive viral replication. Tat is the transcriptional trans-activator of CAEV and Visna Virus.
Rev is the regulator of viral RNA transport in CAEV and Visna Virus. There is another
important element in the CAEV and Visna Virus genome: the RRE (Rev Response Element). It
is a cis functional element that is necessary for transportation of unspliced and partially spliced
mRNA from the nucleus to the cytoplasm through interactions with rev.
Lentiviral Gene Regulation
CAEV and Visna Virus replication is tightly regulated and usually divided into two
phases: early and late (Figure 5). The early phase begins when the virus gains entry into a host
cell by binding to the host cell receptors with its envelope glycoproteins. The virus is then
partially uncoated and the viral RNA is reverse transcribed producing a ds-DNA (double
stranded DNA) copy of the viral genome (called the provirus) that is subsequently integrated into
14

the host cell genome. Transcription of the viral genome in the host cell results in the production
of three types of RNA: Unspliced, singly spliced, and multiply spliced mRNAs (Figure 6). The
multiply spliced mRNAs, which contain rev and tat, are then transported to the cytoplasm and
translated while the unspliced and singly-spliced mRNAs remain trapped in the nucleus. The Tat
protein then upregulates the expression of the viral mRNAs until a critical level of the Rev
protein is reached (Clements and Zink 1996). The late phase of viral gene expression can now
begin and it includes the transport and translation of the unspliced and singly spliced mRNAs
Gag, Pol, and Env.
The unspliced and singly spliced mRNAs contain a stem-loop structure called the Rev
Response Element (RRE). This element is necessary for transport of the mRNAs to the
cytoplasm. The Rev protein returns to the nucleus from the cytoplasm to bind to the RRE. This
complex is then bound by the cellular proteins eIF-5A (eukaryotic initiation factor 5A), CRM1
and RanGTP among others. CRM1 or exportin 1 is the export receptor for Rev and it complexes
with RanGTP in the presence of a NES (Nuclear Export Signal) (Pollard and Malim 1998). The
resulting complex of mRNA/RRE/Rev/CRM1/NES/RanGTP is then competent for transport
through the NPC (Nuclear Pore Complex) (ibid). After the mRNA complex reaches the
cytoplasm, it disassembles and the mRNAs are translated to produce Gag, Pol, and Env proteins.
The Rev protein returns to the nucleus to bind other RREs of unspliced and singly spliced
mRNAs for transport to the cytoplasm. The presence of both rev and the RRE are absolutely
necessary for the completion of viral replication. If either of the two is missing, then viral
replication cannot be completed (Clements and Zink 1996, Luciw 1996, Pollard and Malim
1998).
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Proviral DNA
LTR

AAAA

LTR

AAAA

Rev
Gag, Pol
Env

Rev
AAAA

Rev
AAAA

Rev

AAAA

CRM1

Rev
Rev
Rev
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Rev
AAAA

CRM1

Ran/
GDP

CRM1 Rev
Rev
Rev
Rev
Rev
Ran/
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Cytoplasm

Ran/
GTP
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Figure 5. Lentiviral Gene Regulation.

Gag/Pol 7mG

AAAA

Env 7mG

AAAA

Rev 7mG

AAAA

Figure 6. The Three Classes of mRNAs Produced by CAEV and Visna Virus. The solid lines
represent exons and the dashed lines represent the introns that are removed during splicing. The
stem loop structure represents the RRE that is only present in unspliced and singly spliced
mRNAs.
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CAEV and Visna Virus Rev Protein
The CAEV Rev protein (Rev-C) has a molecular weight of about 18 KiloDaltons (kDa),
while the Visna Virus Rev protein (Rev-V) has a molecular weight of about 22.5 kDa (Saltarelli
et al. 1994, Schoborg and Clements 1994). The amino acid sequences of Rev-C and Rev-V
share little homology when compared to each other, except in two major domain regions: the
basic domain and the leucine rich domain or NES (Nuclear Export Signal) (Figure 7) (Tiley and
Cullen 1992, Saltarelli et al. 1994, Schoborg et al. 1994). The overall function of Rev is the
same in both viruses and is the result of the two conserved domains. The basic domain is located
near the amino-terminal end of the protein and is rich in arginine residues. It contains the
Nuclear Localization Signal (NLS) and the RNA-binding domain (RBD) that is responsible for
Rev binding to the RRE. The basic domain is flanked on both sides by the sequences necessary
for Rev multimerization (Clements and Zink 1996). Mutations involving the arginine residues of
this domain results in a Rev protein unable to bind the RRE or localize to the nucleus (Tiley and
Cullen 1992, Schoborg and Clements 1994, Pollard and Malim 1998). The leucine-rich domain,
or Nuclear Export Signal, is located at the carboxy-terminal end of the protein. Mutations in this
domain do not affect Rev’s ability to localize to the nucleus or its ability to bind the RRE, but
they do diminish Rev’s trans-activation ability (Saltarelli et al. 1994, Pollard and Malim 1998).
Some leucine-rich domain mutants express a dominant negative phenotype and it has therefore
been proposed that the leucine-rich domain interacts with the cellular proteins required for transactivation (Pollard and Malim 1998). A critical level of Rev must be reached in the cytoplasm
before the shift from early phase to late phase gene expression can occur (Schoborg et al. 1994,
Clements and Zink 1996). This is necessary because of the need for Rev to multimerize before
transporting RRE containing mRNAs from the nucleus to the cytoplasm.
Rev Toxicity
Miyazaki et al. have demonstrated HIV-1 Rev is toxic to cultured cells (1995). In addition they
showed that the toxic effect mapped to the basic domain and required nuclear localization, as
17

mutants with the basic domain which are nuclear transport defective do not have a cytotoxic
effect (ibid). The basic domain of HIV-1 Rev has also been shown to have a neurotoxic effect in
mice (Mabrouk et al. 1991). Previous experiments in our laboratory have suggested that Rev-C
is also toxic when expressed in mammalian cells. In these experiments, we were unable to
isolate stable cell lines expressing any Rev protein with an intact basic domain (Table 1). These
results suggest that this toxicity is due to the basic domain of Rev. Because HIV-1 Rev causes
neurotoxicity in mice, Rev-C may be responsible for the neural pathogenesis of CAEV. If the
basic domain is responsible for the toxicity, then we may be able to design a treatment to reduce
the pathology.

Rev-V
MASKESKPSRTTRRDMEPPLRETWNQVLQELVKRQQQEEEEQQGLV
47

SGLQASKADQIYTGNSGDRTTGGIGGKTKKKRGWYKWLRKLRAR

90

91

EKNIPSQFYPNMESNMVGMENLTLETQLEDDMAMDGREWMEWRE 134

135 SAQKEKRKGGLSGQRTNAYPGK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156

Rev-C
1

MDAGARYMRLTGKENWVEVTMDGEKERKREGFTAGQQDIQNSKY 44

45

PDIPTGHSHHGNKSRRRRRKSGFWRWLRGIRQQRNKRKSDSTESLE

91

PCLGALAELTLEGAMEKGPAEAARPSADDGNLDKWMAWRTPQK . . 133

Figure 7. Amino Acid Sequence of CAEV Rev (Rev-C) and Visna Virus Rev (Rev-V). The
Basic Domains are in green and the Leucine Domains (NES) are in red. The C-terminal
sequences are in purple (used to generate the Rev-V and Rev-C antibodies).

18

90

TABLE 1. Toxicity of Rev-C Mutants in Cells
Rev-C Protein
Expressed1

% (number/total #) of cell lines positive, weakly positive
and negative2
+3

+/-3

-3

Rev-C wildtype

0% (0/42)

19% (8/42)

81% (34/42)

Rev-C Delta Leu Rich

0% (0/33)

9% (3/33)

91% (30/33)

Rev-C RR-DL

78% (28/36)

6% (2/36)

16% (6/36)

Rev-C Delta Basic

61% (17/28)

11% (3/28)

28% (8/28)

[From Dr. Robert Schoborg unpublished results]
1

Rev expressing plasmids (described in Figure 13) were constructed by inserting various Rev
encoding cDNA cassettes into the vector pMSG (Pharmacia) downstream from the MMTV LTR.
The plasmid also contains a neomycin resistance gene which allowed G418 selection of stably
transfected Cos-1 cell lines.
2
Cell lines were determined to be positive (+), weakly positive (+/-) or negative for Rev
expression by 35S-labeling and immunoprecipitation with Rev-C specific serum after
dexamethasone induction. A positive signal was a Rev band easily visible on an overnight
exposure and a weakly positive was a Rev band that was visible only after a 5 day exposure. A
cell line was judged negative if no Rev-specific band was visible after a two week exposure.
3
All positive and weakly positive cell lines were also subjected to immunofluorescence analysis
after dexamethasone induction. All positive cell lines were strongly positive in this assay; all
weakly positive cell lines were negative. Random negative cell lines were also tested; they were
all negative in this assay.
CAEV and Visna Virus Rev Response Element
The CAEV Rev Response Element (RRE-C) is located between the nucleotides 7907 and
8108 while the Visna Virus Rev Response Element (RRE-V) is located between the nucleotides
7923 and 8124 (Saltarelli et al. 1990, Tiley and Cullen 1992). Computer analysis predicts that
RRE-C and RRE-V have similar structures. Figure 8 shows the secondary structure of the RREV. HIV-1 Rev has been shown to specifically bind with high affinity to a 13 nucleotide (nt.)
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sequence in stem-loop II of its RRE. The high affinity site must be bound by one Rev molecule
first, and then additional Rev molecules can bind lower affinity sites on the RRE (Malim and
Cullen 1991, Luciw 1996). If the high affinity site in stem-loop II is mutated, then in vitro
binding by Rev and trans-activation of RNAs by Rev are eliminated (ibid).

Figure 8. The Structure of the Visna Virus Rev Response Element (RRE-V). This structure is
similar to the RRE structure found in CAEV (RRE-C). The darker line represents the minimal
amino acid sequence needed to bind Rev-V (nt. 48-169). Reprinted from Tiley and Cullen,
Journal of Virology, Vol. 66, p. 3609-3615.

Computer analysis has shown the RRE-V can be folded into two stable, but different
secondary structures (Tiley and Cullen 1992). The “real” RRE-V has been shown to be located
between nucleotides 7923 and 8124 (RRE-V 7923-8124) based on Rev-V binding and cis-acting
20

experiments. RRE-V8001-8202, which is located between nucleotides 8001and 8202, does not bind
Rev-V in vitro and does not cis-activate RNA transport (ibid). It is used in our experiments as a
negative control.
Like many sequences found in the lentiviruses, there is little amino acid sequence
homology between the different virus strains for either Rev or the RRE. However, the
functionality and overall structure of both the proteins is conserved between the different strains.
For example, it has been shown that the HIV-1 Rev can trans-activate RRE-C at 20% the level
that Rev-C can, while Rev-V and Bovine Leukemia Virus Rex (Rex-B) trans-activate at only
about 10% the level of Rev-C (Saltarelli et al. 1994). Several groups have also shown that HIV
and SIV Rev proteins will trans-activate thru the RREs of other strains with varying efficiencies
(Malim et al. 1989, Sakai et al. 1991, Sakai et al. 1993, Hua et al. 1996). It is likely that studying
the trans-activation of Revs from different lentiviruses in detail will unmask previously
unrecognized structural requirements for Rev/RRE binding and function.
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CHAPTER 2
EXPERIMENTAL APPROACH

As mentioned earlier, the HIV-1 Rev protein has been implicated for
neurotoxicity in mice (Mabrouk 1991) and the CAEV Rev protein is thought to be toxic in
mammalian cells. The basic domain of Rev-C was implicated as the toxic element in those
experiments. In experiments involving transfections of Rev-C mutants, approximately 70% of
the cell lines expressing Rev-C basic domain mutants expressed Rev strongly, while those
containing leucine domain mutants and the wildtype Rev-C did not express Rev well (Table 1).
The leucine domain (NES) mutants and the wildtype Rev-C contained the un-mutated basic
domain which led us to the conclusion that the basic domain may be a toxic element. If the basic
domain is toxic to cells, then perhaps it can be used as a way to inhibit lentiviral replication in
cells or to develop treatment programs to reduce the effects of the neurotoxicity of CAEV on
animals.
Another possible way to inhibit lentiviral replication is by overexpressing copies of the
RRE. The copies might act as decoys and bind Rev resulting in the inhibition of Rev and thus
Env expression. Overexpression of HIV-1 RREs in culture has been shown by several groups to
inhibit HIV-1 replication (Lee et al. 1994, Bahner et al. 1996, Cullen 1998). This has led to the
thought that overexpression of RRE-V might inhibit the replication of visna virus in culture.
Previous experiments in the Schoborg lab have shown that RRE-V can inhibit Env-V expression
by up to 80% and visna virus replication by up to 85% in cell culture. We wanted to improve on
the 85% inhibition of viral replication, so it was necessary to develop better inhibitors. We
hypothesized that the addition of an ORF to the RRE expression plasmids would stabilize the
decoy RNA so the inhibitor RNAs would stay around longer and work better. In adddition, HIV1 studies have shown that SELEX can be used to select RNA ligands that will bind to Rev at
least 10 times better than the wildtype RRE (Giver et al. 1993a, Giver et al. 1993b, Jensen et al.
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1994, Jensen et al. 1995). As a result, we hypothesized that we can use SELEX to make RNA
ligands that will bind Rev-V better than RRE-V and that these aptamers will prove to be stronger
inhibitors of Rev function than the RRE-V decoy.
It has been shown on numerous occasions that lentiviruses can cross-activate across
species. In particular, it has been shown that RRE-C can be cross-activated by many different
Rev proteins including HIV-1 Rev and Rev-V, although at decreased levels (Saltarelli et al.
1994). Previous experiments in the Schoborg lab have also suggested that the RRE-V can be
cross-activated by Rev-C (Hansen 2001). These results led to the hypothesis that Rev-C would
cross-activate RRE-V but at a lower rate than it does RRE-C. If this is true, then it could mean
that an RRE-V decoy might also be able to work as a decoy inhibitor of other related
lentiviruses.
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Hypothesis 1
The Rev-C basic domain mutants, Delta Basic and RR-DL, will be less toxic to cultured
cells than the wildtype Rev-C and the leucine domain mutants, Delta Leu-Rich and LL-FV.

Experimental Design 1
A brief description of the experimental approach used to test this hypothesis is shown in
Figure 9.

Transfections using the six pTracer expression plasmids (Figure 13) into Cos-1 cells
⇓
On days 3, 6, 12, 18, 24 and 30 perform FACS
⇓
Perform statistical analysis using the WinMDI program
⇓
Determine if any of the Rev-C basic domain mutants are less toxic than the wildtype Rev-C or
the Rev-C leucine domain mutants

Figure 9. Summary of Experimental Design 1.
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Hypothesis 2
Overexpression of exogenous RRE-V will inhibit Rev function and thus Env expression
by acting as a decoy for Rev binding.
Experimental Design 2
A brief description of the experimental approaches used to test this hypothesis is shown
in Figure 10.
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Part 1:
Construct Hygromycin resistant
GFP/RRE-V expression plasmids

Part 2:
Transfect Cos-1 cells with Hygromycin
resistant plasmids expressing either
GFP/RRE-V, GFP/RNA-V, GFP/RRE-C
or GFP alone (Figure 15)

⇓

⇓

Co-Transfect pENV/L+ indicator
plasmid with RRE-V expressing
plasmids into Cos-1 cells

Culture cells to produce cell lines
expressing the Hygromycin resistant
plasmids
⇓
Transfect cell lines with the indicator
constructs pEnv/L+ and p1772

⇓
35

⇓
S label transfected Cos-1 cells and collect lysates

⇓
Perform TCA precipitations and quantitate lysates
⇓
Immunoprecipitate Env-V and Rev-V from S35 lysates
⇓
Electrophorese immunoprecipitations on SDS-PAGE gels
⇓
Perform phosporimage analysis to quantitate Env-V and Rev-V expression
⇓
Perform statistical analysis of results
⇓
Determine if overexpression of exogenous RRE-V is able to act as a decoy and
bind Rev-V thereby inhibiting Env expression.
Figure 10. Summary of Experimental Design 2.
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Hypothesis 3
RRE-V ligands that have a higher affinity for Rev-V than the wildtype RRE-V can be
used as decoys to inhibit Rev-V function and viral replication.
Experimental Design 3
A brief description of the experimental approach is shown in Figure 11.
Construct a 60nt oligo with a randomly produced 30 nt. sequence in the middle and PCR
amplify
⇓
In vitro transcribe the DNA to produce RNA
⇓
RNA binding to GST and Rev-V GST fusion proteins
⇓
Reverse transcription of the bound RNA to produce DNA
⇓
PCR amplification of the DNA
⇓
One round of SELEX has been completed, repeat until nine rounds have been completed
⇓
RNA binding assays comparing the wildtype RRE-V and the SELEX RRE-V transcript
⇓
Electrophorese samples on 6% and 12% Urea/Polyacrylamide gels
⇓
Competition RNA binding assays comparing wt. RRE-V and the SELEX RRE-V transcript
⇓
Electrophorese samples on 3% NuSieve formaldehyde gels
⇓
Determine if the SELEX RRE-V ligand is a better binder to Rev-V than the wildtype RRE-V
Figure 11. Summary of Experimental Design 3.
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Hypothesis 4
Rev-C will trans-activate through the RRE-V, but at a lower efficiency than Rev-V. The
lower efficiency is because it does not bind as well to RRE-V.
Experimental Design 4
A brief description of the experimental approach used to test this hypothesis is shown in
Figure 12.

Part 1:
Co-Transfect pEnv/L(-) indicator plasmid with Rev-V, Rev-C, and a mock (Figure 24) into
Cos-1 cells
⇓
35

S label transfected Cos-1 cells and collect lysates
⇓

Perform TCA precipitations and quantitate lysates
⇓
Immunoprecipitate Env-V and Rev-V from 35S lysates
⇓
Electrophorese immunoprecipitations on SDS-PAGE gels
⇓
Perform phosporimage analysis to quantitate Env-V and Rev-V expression
⇓
Perform statistical analysis of results
⇓
Determine if Rev-C does activate RRE-V, but at a lower activation rate than Rev-V

Figure 12. Summary of Experimental Design 4.
28

Part 2:
In vitro translate Rev-V, Rev-C (+) and Rev-C (-) with 35S
⇓
Perform RNA binding assays using 32P labeled RRE-V, RRE-C (+) and RRE-C(-)
⇓
Electrophorese RNA binding assays on 6% urea/polyacrylamide gels
⇓
Perform phosporimage analysis to quantitate Rev-C's affinity for RRE-V
⇓
Perform statistical analysis
⇓
Determine if the reason for a decrease in Rev-C's ability to activate RRE-V is because it does
not bind RRE-V as well
Figure 12 (continued).
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CHAPTER 3
MATERIALS AND METHODS

Bacterial Strains
GST and GST-Rev-V cell lysates were isolated from BL21 E. coli, which was a gift from
Dr. Bryan Cullen (Malim and Cullen 1991).
Cell Lines
Cos-1 cells were used in all procedures requiring cell culture. Cos-1 are derived from
simian kidney cell lines that were transformed with the SV40 T antigen. They were maintained
in Dulbecco’s Modified Eagle Medium (GlutaMAX 1 + high glucose + 25 mM HEPES buffer +
pyridoxine HCL) (Life Technologies) + 10% heat inactivated Fetal Bovine Serum (Atlanta
Biologicals) + 10 mM MEM Sodium Pyruvate Solution (Life Technologies) + 0.05mg/ml
Gentamycin (Cellgro) + 1ug/ml Fungizone (Life Technologies).
Antibodies
Several different antibodies were used in these projects. Rabbit polyclonal Rev-C
antisera was used in the Rev-C/ RRE binding assays. It is directed against the final 19 carboxyterminus amino acids (SADDGNLDKWMAWRTPQ) of Rev-C (Saltarelli et al. 1994). Affinity
purified Rev-C antisera was used in all other experiments. Rabbit polyclonal Rev-V antisera was
used in the Rev-V/ RRE binding assays. Affinity purified Rev-V antisera was used in all other
experiments. It is directed against the final 15 carboxy-terminus amino acids
(KGGLSGQRTNAYPGK) of Rev-V (Schoborg and Clements 1994). Antibody to Env-V (visna
Env) was provided by Dr. Andrés de la Concha-Bermejillo (Texas A & M University).
Rev-C Expression Plasmids
There were several Rev-C expression plasmids used to work on the Rev Toxicity project.
They were made by using the indicator construct pTracer which expresses the green fluorescent
protein (GFP) that was used to identify plasmid carrying cells through FACS analysis. In these
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plasmids, the CMV IE promoter expresses the GFP protein and the SV40 early promoter
expresses the Rev-C proteins. All of these plasmids have been sequenced and shown to express
the appropriate Rev protein at similar levels (data not shown).

A.

PTracer

PTracer Rev-C

GFP
CMV IE

GFP
Poly A

CMV IE

Poly A

Rev-C
SV40

SV40

B.
Rev-C wt
Rev-C RR-DL
Rev-C Delta Basic

GNKSRRRRRKSGFWRWLRGIRQQRNKRKSDSTES
GNKSRDLRRKSGFWRWLRGIRQQRNKRKSDSTES
GNKS-----------------------------------------------------SDSTES

Rev-C wt
GALAELTLEGAMEKGP
Rev-C LL-FV
GALAEFTVEGAMEKGP
Rev-C Delta Leu-Rich GALAE-----------------KGP

Figure 13. Rev-C/GFP Expression Constructs. A.) pTracer indicator construct alone and
pTracer indicator construct with the Rev-C expression casette inserted. B.) Diagram showing
where the different mutations were made in the basic and leucine domains to produce the Rev-C
mutants.
Transformations
Epicurean Coli XL-1 Blue MRF’ supercompetent cells (Stratagene) were first thawed on
ice and then 100 ul were aliquoted into sterile, chilled on ice, 17 X 100 mM polypropylene tubes
(Fisher). One point seven ul of β−mercaptoethanol was added to each tube, followed by gentle
mixing and then incubation of the tubes on ice for 10 minutes mixing every 2 minutes. One ul of
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plasmid DNA or 3 ul of ligation mix was added to this reaction tube. The tubes were gently
mixed and placed on ice for 30 minutes. This was followed by 45 seconds in a 42°C water bath
and then placed back on ice for 2 minutes. Nine hundred ul of SOC media (2% bacto-tryptone,
0.5% bacto-yeast extract, 0.05% NaCl, 20 mM glucose) was then added to each tube followed by
an hour incubation at 37°C while shaking at about 225 rpm.
Antibiotic Selection of Transformants
Transformed cells were plated on L Broth agar plates (1.0% NaCL, 1.0% bacto-tryptone,
0.5% bacto-yeast extract, 1.5% bacto-agar) using the appropriate antibiotic. The pTracer based
plasmids required 250 ug/ml Zeocin and all ligation transformations required 50 ug/ml
Ampicillin per plate. The pTracer plasmid transformations were plated out on 3 plates at
different volumes: 1 ul, 5 ul and 10 ul. The ligation transformations were plated out on 4 plates
at volumes of 10 ul, 25 ul, 50 ul, and 100 ul. The plates were incubated overnight at 37°C.
Mini-Prep
Followed laboratory protocol as described by Dr. Michelle Abelson (2000).
Large Scale Plasmid Preparations
The Concert High Purity Plasmid Maxiprep kit purchased from Life Technologies, was
used to do large scale preparations of DNA. The manufacturer’s directions were followed
completely. Upon completion of the plasmid prep, the concentration of each DNA was acquired
by diluting each 1:200 in double distilled water (ddH20) and measuring its optical density at both
260nm and 280nm wavelengths using the Spectronic Spec 600 Spectrophotometer. Using the
resulting 260 optical density (OD), the amount of DNA was calculated as follows: OD260 X 50
(conversion factor) X 200 (dilution factor) / 1000 ul = ug/ul. The plasmid preps were then
checked for purity and positive identification by restriction digests followed by electrophoresis
on an agarose gel with known standards. The plasmids were then stored at -20°C.
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EtOH Precipitation of DNA for Transfection
Before every transfection, the DNAs were purified by 3M NaOAc / Ethanol (EtOH)
precipitation. To the volume of any DNA, the following was added: 1/10 volume of 3M NaOAc
pH 5.2 and 2 X volume of 95% EtOH. They were vortexed and stored at -80°C for one hour.
Samples were then centrifuged at 12,000 rpm, 4°C for 15 minutes. The supernatants were
discarded and the pellets were washed 2 X with 1 ml of 70% EtOH, vortexed and centrifuged at
12,000 rpm, 4°C for 5 minutes. Supernatants were removed and the pellets were dried for 5-10
minutes in the speed vac. The pellets were then resuspended in nuclease free H2O and frozen at 20°C.
Transfection of Mammalian Cells
We used 2 different transfection protocols: Lipofectin/OPTI-MEM 1 and TransIT-LT1.
Transfections were done in Cos-1 cells plated at a density of 4.5 X 105 cells per well in 4 mls of
media in a 6 well plate (Costar) or 2.5 X 106 cells in 100 mM plates (Corning) in 10 mls of
media. The lipofectin/OPTI-MEM 1 transfections were set up in 15 ml Polystyrene tubes
(Fisher). For each transfection 75 ul of lipofectin and 300 ul OPTI-MEM 1 reduced serum
medium [MEM (high glucose + 25 mM HEPES buffer + pyridoxine HCL) + 1 X HEPES buffer
+ 2.4 mg/ml sodium bicarbonate + L- glutatmine] (Life Technologies) was added to 1
polystyrene tube and incubated at RT° for 40 minutes. Each DNA to be transfected was added to
600 ul of OPTI-MEM 1 in a polystyrene tube and then sterile filtered into a new polystyrene tube
(using a sterile cameo filter and a 1 ml syringe). Six hundred microliters of the lipofectin/OPTIMEM 1 mix was then added to the DNA/OPTI-MEM 1 mix and incubated for 10 minutes at
RT°. During the 10 minute incubation time period, each of the 100 mm plates of Cos cells had
the media aspirated and re-fed with 6 mls of OPTI-MEM 1. To each DNA/OPTI-MEM
1/lipofectin mix, 3.3 mls of OPTI-MEM 1 were added to bring the total volume of transfection
mix up to 4.5mls. The OPTI-MEM 1 was then aspirated from each plate and the 4.5 mls of
transfection mix was added to each plate. Each plate was then swirled to mix and placed in the
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incubator (37°C with 5% CO2) for 6-8 hours. The plates were then removed from the incubator,
the transfection mix was aspirated, and the cells were re-fed with 10 mls of media and placed
back into the incubator.
Transfections done with TransIT-LT1 were set up in sterile 1.5 ml screw cap tubes. For
each reaction 100 ul OPTI-MEM 1 + 6 ul TransIT-LT1 were added to each tube, gently mixed,
and incubated at RT° for 20 minutes. Two ug of DNA was added for each reaction to the
appropriate tube, gently mixed, and incubated at RT° for 20 minutes. The media was aspirated
from each well of the plated Cos-1 cells (in 6 well plates) and the cells were re-fed with 2 mls of
media. The DNA/OPTI-MEM/TransIT-LT1 mix was then added drop-wise to the appropriate
well. The plates were swirled to mix and then placed in the incubator until ready for labeling.
Preparation of Cells for FACS
Transfected COS-1 cells expressing GFP were harvested and prepared for FACS
(Fluorescent Activated Cell Sorter) by first aspirating the media from each well and placing it
into a labeled 15ml polypropylene tube (Fisher) on ice. Each well was then washed twice with 3
mls of 1 X PBS (Phosphate Buffered Saline). Zero point five ml of 1 X Trypsin (Life
Technologies) was then added to each well and then removed. The 6 well plate was then placed
into the incubator for 3-5 minutes. The original supernatant from each well was then added back
to its well and washed up and down in the pipette until all cells were lifted from the well. The
cells/supernatant were then placed back into the 15 ml polypropylene tube and put back onto ice.
A serum cushion was then added to each tube by using a plugged Pasteur pipette to carefully add
approximately 0.5 ml of 10% FCS (Fetal Calf Serum) to the bottom of the tube so that a cushion
was formed and then it was placed back on ice. The tubes were centrifuged at 1500 rpm for 5
minutes at 4°C. An unplugged pipette was used to aspirate off the supernatant down to the pellet
and the pellet was then resuspended in 1 ml 1 X PBS/ 5mM EDTA. The mix was pipetted up
and down and then moved into a 1.5 ml flip top tube. The tubes were centrifuged for 3 minutes
at 2000 rpm at 4°C. The supernatant was aspirated off down to the pellet and the pellet was then
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resuspended in 1 ml 1 X PBS/ 5mM EDTA. The mix was filtered through Spectra/Mesh
Polypropylene filter (105 um opening, 20% open area, 212 um thick, stock # 146 436) into a 5
ml Flow Cytometry tube provided by Scott Reynolds and then placed on ice. The samples then
had FACS analysis (Becton Dickson FACScan) performed on them by Scott Reynolds. The
resulting data were analyzed using the WinMDI program.
Gel Purification of DNA and Ligations
Followed laboratory protocol as described by Dr. Michelle Abelson (2000).
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S Labeling and Harvesting of Cos-1 Cells, TCA Precipitation and Quantification of 35S Labeled
Cell Lysates, and Immunoprecipitation of Env and Rev Proteins
Followed laboratory protocol as described by Lillia Holmes (1997).
Gel Electrophoresis
Several types of gel electorphoresis were used while performing these experiments. They

are SDS PAGE, urea/polyacrylamide, and formaldehyde gels. SDS PAGE gels were run to
quantitate immunoprecipitations and protein expression. Samples were boiled for 10 minutes,
quenched on ice, and centrifuged briefly. Rev immunoprecipitations were electrophoresed on
SDS PAGE gels that included a 15% running gel (6 ml 37:5:1 acrylamide/bis (AMRESCO), 5 ml
ddH20, 3.75 ml 1.5 M Tris pH 8.8, 0.15 10% SDS, 0.15 ml 10% APS, 0.75 g Sucrose, 5 ul
TEMED) and a 5% stacking gel (1.3 ml 37:5:1 acrylamide/bis, 6 ml ddH20, 2.5 ml 0.5 M Tris
pH 6.8, 0.1 ml 10% SDS, 0.1 ml 10% APS, 10 ul TEMED). Env immunoprecipitations were
electrophoresed on SDS PAGE gels that included a 10% running gel (4 ml 37:5:1 acrylamide/bis
(AMRESCO), 7 ml ddH20, 3.75 ml 1.5 M Tris pH 8.8, 0.15 10% SDS, 0.15 ml 10% APS, 0.75 g
Sucrose, 5 ul TEMED) and a 5% stacking gel. The gels were run in 1 X Tris/Glycine “E” buffer
(25mM Tris, 250 mM Glycine, 0.1%SDS) on either a Hoeffer SE 600 Gel apparatus or a BioRad
Mini PROTEAN 3 apparatus. The gels were run at 100 volts until the dye front passed through
the stacking gel and then the voltage was turned up to 300 volts. The gels were run until the dye
front reached the bottom, they were then removed and placed in protein gel fixer (30% methanol,
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10% acetic acid) for 30 minutes, and then fluorographed with Entensify solutions A and B
(DuPont/NEN Research Products) for 30 minutes in each solution. The gels were then dried for
3 hours on a vacuum gel dryer at 65°C, placed on a phosphor screen for later quantification
analysis and then put up on x-ray film (Kodak) with intensifying screens at -70°C.
Phosporimaging analysis was done using a BioRad FX imager with Quantity One software v2.4.
Binding assays and RNA samples were run on 6% and 12% urea/polyacrylamide gels.
The samples were resuspended in sequencing dye (For 10 mls: 10 ml deionized formamide + 5
mg xylene cyanol + 5 mg bromophenol blue + 200 ul 0.5 M EDTA). These gels were run on
either the Hoeffer or the BioRad apparatii. Samples were boiled for 10 minutes, quenched on
ice, and centrifuged briefly. They were then electrophoresed on either a 6% urea/polyacrylamide
(for 200 mls: 96 g Urea + 30 mls 19:1 acrylamide/bis (AMRESCO) + 40 mls 5 X TBE) or a
12% urea/polyacrylamide gel (for 200 mls: 192 g Urea + 30 mls 19:1 acrylamide/bis
(AMRESCO) + 40 mls 5 X TBE). The gels were run at 300 volts until the second dye front
reached the bottom, they were then removed and placed in sequencing gel fixer (20% methanol,
10% acetic acid) for 30 minutes. The gels were then dried for 3 hours on a vacuum gel dryer at
65°C, placed on a phosphor screen screen for later quantification analysis and then put up on xray film (Kodak) with intensifying screens at -70°C. Phosporimaging analysis was done using a
BioRad FX imager with Quantity One software v2.4. RNA binding assays were run on 1%
MOPS formaldehyde gels. Samples were resuspended in a sample buffer made up of: 1 ug
RNA + DEPC H20 up to 2.25 ul + 1 ul 10 X MOPS, 1.75 formaldehyde + 5 ul deionized
formamide + 1ul EtBr. Samples were heated to 55°C for 10 min and then 2 ul RNA loading dye
were added to each sample. Samples were then immediately loaded onto the MOPS
formaldehyde gel (for 80 mls: 57.6 mls DEPC H20 + 0.8 g agarose + 8 ml 10 X MOPS, that was
heated and cooled, followed by the addition of 14.4 mls formaldehyde). The gels were
electrophoresed (in 1 X MOPS buffer) at 55 volts for 6-8 hours, removed, placed on the vacuum
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gel dryer for 3 hours at 50°C, placed on a phosphor screen for later quantification analysis, and
then put up on x-ray film (Fuji Safelight) with intensifying screens at -70°C.
Phenol/Chisom Extractions
There were 2 methods used to phenol chisom extract samples throughout these
experiments. One method employed the use of phase lock tubes purchased from 5 Prime → 3
Prime, Inc. The manufacturer's instructions were followed to complete the extraction.
Otherwise samples were phenol/chisom extracted by adding equal volume of phenol/chisom (1:1
solution, chisom is 24:1 solution of chloroform and isoamyl alcohol), vortexing, and centrifuging
for 3 minutes, 4°C at 12,000 rpm. The aqueous layer (top layer) was removed to a new tube, an
equal volume of chisom was added and the tube was vortexed and spun again. This step was
repeated and the aqueous layer was then EtOH precipitated, dried in the speed vac, and
resuspended in the appropriate amount of H2O.
In Vitro Transcription of 32P Labeled RREs
The following RREs were in vitro transcribed for various experiments: RRE-V, RNA-V,
RRE-C (+) and RRE-C (-). Linearized DNA preparations of each pGEM RRE clone were first
heated at 55°C for 10 minutes and then quenched on ice. The reactions were set up in 1.5 ml
screw cap tubes: 4 ul 5 X T7 or SP6 Polymerase buffer (which ever is required based on the
promoter present in each DNA) (Promega) + 2 ul 100 mM DTT + 2 ul 5 mM ribonucleotides A,
C and G + 2 ul 100 uM rUTP + 5 ul alpha 32P rUTP + 1 ul DNA template + 1 ul RNasin
(400u/ul) (Promega) + 1 ul T7 or SP6 RNA Polymerase + 2 ul DEPC treated H2O. The tubes
were placed at 37°C for 1 hour, then 16 ul DEPC treated H2O was added along with 4 ul 5 X
transcription buffer and 2 ul RQ1DNase (Promega). The tubes were then placed at 37°C for 30
minutes, phenol/chisom extracted, EtOH precipitated, dried in the speed vac, resuspended in 200
ul DEPC treated H2O, counted, and stored at -20°C.
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Construction of the Oligo Used to Make the SELEX RNA Aptamers
An oligo was designed to develop the random RNA ligands for the SELEX protocol.
The oligo consisted of a SP6 promoter with 30 nt. of unknown nucleotides that was cloned into a
pCR vector (T7 promoter) using the TA Cloning Kit by Invitrogen. This resulted in a known 60
nt. oligo with a T7 promoter sequence on the 5’ end, a SP6 promoter sequence on the 3’ end and
a 30 nt. random sequence in the middle. This was then PCR amplified using the T7 and SP6
promoters and the DNA was then in vitro transcribed using T7 polymerase resulting in a pool of
RNAs that had known terminal sequences and random interior sequences.
SELEX: Cell Lysate Preparation
BL21 E.coli clones expressing GST or GST-Rev-V fusion protein were streaked onto L
Broth agar plates (1.0% NaCL, 1.0% bacto-tryptone, 0.5% bacto-yeast extract, 1.5% bacto-agar)
containing 50 ug/ml of Ampicillin and placed at 37°C overnight. One isolated colony was
selected from each plate and added to a sterile test tube along with 5 ml LB-Amp and then placed
on a shaker at 200 rpm overnight at 37°C. Each 5ml cell culture was then poured into a sterile
1L flask with 500 ml LB-Amp and grown until the OD at 600nm reached 0.6 - 0.8. Five hundred
five ul of IPTG (100 mM) was then added to each flask and incubated for 90 minutes at 37°C on
a shaker. The cells were harvested by pouring the contents of each 1L flask into 2, 500 ml
centrifuge tubes followed by centrifugation for 10 minutes at 7,000 rpm. The supernatant was
discarded and 4.75 ml of TSE Buffer (50mM Tris pH 8.0 + 25%sucrose + 1mM EDTA) was
added to the tubes. The mix was then vortexed well to make a homogeneous suspension. The
suspension was transfered to Oak-ridge tubes (50 ml) and the following was added: 12 ul of
PMSF (100mM), 5 ul Leupeptin (10mg/ml), 5 ul Pepstatin (10mg/ml) and 125 ul Lysozyme
(20mg/ml). The tubes were mixed well and then incubated at room temperature (RT) for 5
minutes. The following was then added to each tube: 32.5 ul 2M MgCl2, 6.5 ul 1M MnCl2, and
6.5 ul DNase, mixed well and incubated in a 37°C water bath for 15 minutes. Then we added the
following: 850 ul 10X PBS, 425 ul 20 % Triton X-100, 425 ul Tween-20 and 85 ul 1M DTT,
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mixed well, and then centrifuged tubes at 10,000 rpm for 10 minutes. The cell lysates were
transfered to new Oak-ridge tubes and the lysate's volume was measured. We added 10% of the
lysate's volume in glycerol, mixed well, aliquoted 550 ul of the lysate into 1.5 ml flip-top tubes,
and stored at -20°C .
SELEX: Transcription
The in vitro transcription was set up in a 1.5 ml screw-cap tube and the following
reagents were added: 30 ul of cDNA, 28 ul DEPC treated water, 20 ul 5X transcription buffer, 10
ul rNTP's, 10 ul 100 mM DTT, 0.4 ul 1 M MgCl2, and 1.6 ul SP6 polymerase for a total volume
of 100 ul. The tube was placed in a 37°C water bath for 2 hours and then 2 ul RQ1DNase was
added and the tube was incubated for 30 minutes at 37°C (water bath). We removed 6 ul and
put into 2 - 0.5 ml flip top tubes as 3 ul aliquots and added 1 ul RNase A (10mg/ml) to one tube
and nothing to the other tube. The 2 tubes were incubated at 37°C (water bath) for 30 minutes.
The 2 samples were then run out on a 1.5 % agarose gel TBE+EtBr with a 100 bp marker to
ensure that RNA had been made. There should not be a band seen in the Rnase A sample lane,
but the other lane should show a 100 bp product. We took the remaining volume from the in
vitro transcription and did an organic solvent extraction (phenol/chisom extraction) by adding
100 ul of DEPC treated water and transferring that volume (approximately 200 ul volume) to an
already spun down (30 seconds) phase lock tube. We then added the same volume (200 ul) of
Phenol/chisom (for RNA use), inverted the tube and centrifuged the tube for two minutes at
10,000 rpm. Next we added 200 ul of Chisom (for RNA use), inverted the tube and centrifuged
for 2 minutes at 10,000 rpm. We repeated the last step again and then we removed the aqueous
layer to a new 1.5 ml screw cap tube and measured its volume. We then ethanol precipitated the
RNA according to its volume and using RNA reagents and upon completion of the EtOH
precipitation, the pellet was dried in the speed vacuum (Savant). The RNA pellet was
resuspended in 200 ul DEPC treated water, divided evenly into 2 screw cap tubes, and stored at 80°C.
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SELEX: Binding
One tube of GST-Rev-V cell lysate (Rounds 1-9) and 1 tube of GST cell lysate (Rounds
5-9) were thawed at room temperature. The cell lysates were divided between two 1.5 ml fliptop tubes (250 ul each, total of 4 tubes if using both cell lysates). We added the same volume of
50 mM Tris pH 8.0 to each tube along with 25 ul of Glutathione agarose beads. The tubes were
placed on the rotator in the 4°C walk-in room for 30 minutes and then centrifuged at 4°C and
12,000 rpm for 3 minutes. The supernatants were discarded and the beads were washed 4 X with
1 ml of 50 mM Tris pH 8.0. Five hundred ul of 1X CH running modified buffer (For a 2 X
solution of 500 mls: 453.5 ml DEPC treated water, 30 ml 5M NaCl2, 10 ml 1M Tris pH 8.0,
0.0305 g MgCl2, and 6.5 ml BIACore NP-40) was added to the beads, and using a large orifice
tip removed the beads from both tubes (2 tubes per cell lysate type) into one 1.5 ml screw cap
tube (one tube per cell lysate type). Another 500 ul of 1X CH running modified buffer was
added to make sure all of the beads were removed. The tubes were centrifuged at 4°C, 12,000
rpm for 3 minutes and the supernatant was discarded. For Rounds 1-4 (Worked with GST-RevV tube only) we added 100 ul 1X CH running modified buffer + 100 ul in vitro transcribed RNA
+ 4 ul Rnasin. The tube was attached to a styrofoam rack which was attached to the vortex and
then the tube was vortexed (lightly) continuously for 1 hour at a speed of 3 or 4 followed by
centrifugation at 4°C, 12,000 rpm for 3 minutes. (For Rounds 5-9: stored the GST-Rev-V tube
at 4°C for later and initially work with the GST tube of beads by adding 100 ul 1X CH running
modified buffer + 100 ul in vitro transcribed RNA + 4 ul Rnasin. The tube was attached to a
styrofoam rack which was attached to the vortex and then the tube was vortexed continuously for
1 hour at a speed of 3 or 4 followed by centrifugation at 4°C, 12,000 rpm for 3 minutes. The
liquid from the beads was transferred to the GST-Rev-V tube of beads and that tube was attached
to the styrofoam rack which was attached to the vortex and vortexed continuously for 1 hour at a
speed of 3 or 4 followed by centrifugation at 4°C, 12,000 rpm for 3 minutes). The supernatant
was discarded and the bead were washed 6 X with 1 ml of 1X CH running modified buffer
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followed by centrifugation at 4°C, 12,000 rpm for 3 minutes. Four hundred ul of pre-warmed
(62°C) Proteinase K digestion buffer (for 1 ml: 780 ul of DEPC treated water, 20 ul of 1M
Tris.Cl pH 7.5, 50 ul 0.4M EDTA pH 8.0, 50 ul 10% SDS and 100 ul of 10 mg/ml Proteinase K)
was added to the tube and incubated at 62°C for 2 hours. The tube was boiled for 5 minutes to
release the bound RNA from the beads and then centrifuged at 4°C, 12,000 rpm for 3 minutes.
The supernatant (approximately 400 ul volume) was transferred to an already spun down (30
seconds) phase lock tube and a Phenol/Chisom extraction (follow protocol as done earlier) was
done. The aqueous layer was transferred to a 1.5 ml screw cap tube its volume was measured in
order to EtOH precipitate the RNA as usual. The pellet was dried for 5 minutes in the speed
vaccuum and resuspended in 30 ul DEPC treated water. This RNA was used to set up the RT
(Reverse Transcriptase) reaction.
SELEX: Reverse Transcription
Four 0.5 flip top tubes tubes were irradiated for 20 minutes before setting up the
reactions. We divided the 30 ul RNA sample resulting from the binding procedure into 3 tubes
(10 ul in each tube) and added 1 ul of DEPC treated water to each tube. A negative control using
11 ul of DEPC treated water was set up. One ul of primer SS (Sal-Sma selex) (1 ug/ul) was
added to each tube, the tubes were placed at 70oC for 10 minutes and then quenched on ice. Four
ul 5X RT buffer (Promega) + 2 ul 0.1 M DTT (Promega) + 1 ul 10 mM dNTP's (Perkin Elmer)
was added to each tube, mixed well and placed at 42oC for 2 minutes. One ul RT enzyme (MMLV from Promega) was added to each tube and the tubes were placed at 42oC for 90 minutes
and then transfered to 70oC for 15 minutes. They were centrifuged briefly and then the DNAs
were ready for the PCR step.
SELEX: PCR
The negative control is the negative reaction tube from the previous RT reaction while
the positive control is a dilution of the DNA SELEX template (1:25). There are 11 reactions
total (negative, positive, and three for each of the three RT reactions). We added 78.8 ul of PCR
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water to both the negative and positive control tubes and 73.3 ul of PCR water to each of the
sample tubes. We made a master mix with the following reagents (For 11 reactions: negative,
positive, and three samples): 110 ul 10 X PCR buffer (Perkin Elmer), 22 ul 10 mM dNTP's
(Perkin Elmer), 66 ul 25 mM MgCl2 (Perkin Elmer), 5.5 ul primer SS (Sal-Sma selex), 7.7 ul
primer SCH (SP6-Cla-Hind selex), and 11.0 ul Amplitaq Gold enzyme (Perkin Elmer). We
added 20.2 ul of the master mix to each tube. We added 1 ul of the negative control from the
previous RT reaction to the negative control tube, 1 ul of the 1:25 dilution of the DNA selex
template to the positive control tube, and 6.5 ul from the each of the three previous RT reactions
to the three sample tubes. The tubes were placed in the thermocylcer and the program named
"CAPCR" was run (PCR Cycle: step # 1: 94°C for 30 seconds, step # 2: 65°C for 1 minute, step
# 3: 68°C for 1 minute, step # 4: go to step # 1 for 39 cycles, step # 5: 68°C for 7 minutes, and
step # 6: 4°C overnight). Five ul was removed from each tube and electrophoresed on a 1.5 %
agarose gel TBE + EtBr along with a 100 bp marker. If a 100 bp product was present in each
sample lane and nothing was in the negative lane, then the 3 tubes from the reaction samples
were pooled together and an organic solvent extraction was performed, but before starting the
extraction a 5 ul aliquot of the pooled DNA was saved and stored at -20°C. The remaining
volume of DNA (approximately 280 ul volume) was transfered to an already spun down (30
seconds) phase lock tube for the Phenol/Chisom extraction. After the extraction was completed,
the aqueous layer was removed to a 1.5 ml screw cap tube and the volume was measured in order
to EtOH precipitate the RNA as usual. The pellet was dried in the speed vaccuum, resuspended
in 50ul DEPC treated water, and stored at-20°C. One round of SELEX has been completed and
the DNA is now ready for the next round of SELEX (9 total rounds were done).
SELEX: RNA Binding Assays
These were done to determine the minimum amount of protein necessary for binding
(saturation point of binding). The SELEX binding reactions were done with 5 fold serial
dilutions of GST-Rev-V. The reactions were built in 1.5 ml screw cap tubes: 250 ul GST-Rev42

V dilution + 250 ul 50 mM Tris pH 8.0 + 25 ul glutathione agarose beads (Amersham
Pharmacia). The tubes were attached to a rotator at 4°C for 30 minutes and then centrifuged for
3 minutes 12,000 rpm at 4°C. The supernatants were discarded and the beads were washed 4
times with 1 ml 50 mM Tris pH 8.0 and then washed twice with 1 ml 1 X CH running buffer
(centrifuged for 3 minutes 12,000 rpm at 4°C after each wash). After the last wash, the
supernatants were discarded and the pellets were resuspended in 100 ul 1 X CH running buffer +
100 ul in vitro transcribed 32P RRE-V probe + 4 ul RNasin. The tubes were attached to a vortex
and vortexed at a speed of 3-4 for 1 hour followed by centrifugation for 3 minutes at 12,000
rpmc 4°C. The supernatants were discarded and the were pellets washed 6 times with 1 X CH
running buffer and resuspended in 25 ul sequencing dye. The samples were boiled for 10
minutes, quenched on ice, centrifuged briefly, and run out on a 6% urea/polyacrylamide gel.
SELEX: Competition Assays
Based on the results from the RNA binding assays, it was determined that a 1:125
dilution of GST-Rev-V cell lysate would provide the minimum amount of protein needed to
maximize the binding reaction. We did one dilution of the cell lysate in a 50 ml conical tube (for
16 reactions): 32 ul of GST-Rev-V + 3968 ul storage buffer (what the cell lysates were
resuspended in for freezing) + 400 ul glutathione agarose beads + 4000 ul 50mM Tris pH 8.0.
The tube was then placed on the rotator for 30 minutes at 4°C followed by centrifugation at
5,000 rpm, 4°C, for 3 minutes. The supernatant was discarded and the pellet was washed 4
times with 5 ml 50mM Tris pH 8.0 and then washed twice with 5 ml 1 X CH running buffer
(centrifuged each time at 5,000 rpm, 4°C, for 3 minutes). After the final wash, the beads were
resuspended in 1600 ul 1 X CH running buffer, mixed and 112 ul of beads/buffer was aliquoted
into 14, 1.5 ml screw cap tubes. Two sets of competition assays were done; one involving the
unlabeled wildtype RRE and one involving the unlabeled RNA-V (negative control). The
competitor was diluted 5 fold over 5 dilutions. There were 7 tubes for each assay (7 for RRE-V
and 7 for the SELEX ligand): Undiluted tube, 1:5 tube, 1:25 tube, 1:125 tube, 1:625 tube,
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1:3125 tube, and a tube with no competitor (positive control). To each tube 112 ul beads/CH
buffer and 1 ul (2ug) of the appropriate competitor (1 ul DEPC H20 was added to the positive
control) was added followed by 100 ul of a mix consisting of labeled RRE-V or SELEX ligand,
DEPC H20 and RNasin (1,000,000 cpm’s of each probe + 2 ul RNasin + DEPC H20 up to 100
ul). The tubes were attached to a vortex and vortexed at a speed of 3-4 for 1 hour followed by
centrifugation for 3 minutes at 12,000 rpm, 4°C. The supernatants were discarded and the pellets
were washed 6 times with 1 X CH running buffer and resuspended in 25 ul sequencing dye. The
samples were boiled for 10 minutes, quenched on ice, centrifuged briefly, and then
electrophoresed on either a 6% urea/polyacrylamide gel (RRE-V samples) or a 12%
urea/polyacrylamide gel (SELEX ligands).
In Vitro Transcription,Translation and Immunoprecipitation of IVT’s
Followed laboratory protocol as described by Dr. Michelle Abelson (2000).
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CHAPTER 4
RESULTS HYPOTHESIS 1

FACS Analysis of Cells Expressing Rev-C
Previous data in the lab had indicated that Rev-C is toxic when expressed in mammalian
cells. The basic domain had been implicated as the cause of the toxicity. If this is true, then
perhaps treatments can be devised to counteract the toxic effects of Rev in vivo. To determine if
the basic domain of Rev is acutely toxic, transfections were done in Cos-1 cells using
pTracer/Rev-C mutant expression plasmids. The transfections were done using the lipofectin
method (described previously). Three days post-transfection, we split the cells and performed
FACS analysis on 20,000 cells; the remaining cells were replated in new media. We split, FACS
analyzed and replated the cells also on days 6, 12, 18, 24, and 30 post-transfection. FACS
analysis was done on the transfected cells to determine the number of GFP events from each time
point. A graph was produced based on the WinMDI analysis of each time point as shown in
Figure 14.
Based on the graphical analysis done, it apppears that there was no significant difference
in the number of GFP expressing cells in each transfection. These results show that all of the
plasmids, including pTracer alone, were maintained at similar levels in the populations of
cultured cells during the entire 30-day time period. If the Rev protein was acutely toxic, then we
would expect to see a significant difference in the number of cells expressing GFP. All of the
Rev-C transfected cells would have died off quickly resulting in low amounts of GFP expressed,
while the cells transfected with pTracer alone would have maintained a much higher level of
GFP expression. If the basic domain was responsible for the toxicity of Rev, then the cells
transfected with the un-mutated basic domain plasmids (Sense, Delta Leu-Rich, and LL-FV)
should have died off quickly resulting in a sharp decline in the amount of GFP expressed and the
cells transfected with the mutated basic domain plasmids (RR-DL and Delta Basic) should have
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been less toxic and thus GFP expression would have been maintained longer. The pTracer alone
(+ control) transfected cells should have maintained the highest level of GFP expression over
time because they do not contain any Rev sequences.
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Figure 14. FACS Analysis of pTracer/Rev-C Transfected Cells. Cos-1 cells were transfected,
using the Lipofectin/OPTI-MEM method, with each of the pTracer/Rev-C expression plasmids
(described previously and indicated by the key on the right). Cos-1 alone (no plasmid
transfected) acted as the mock transfection. The 8 transfections (5 ug of DNA/Tx) were done in
100mm plates with a cell density of 2.5 X 106 cells/plate. Cells were split and re-fed every 3
days. On days 3, 6, 12, 18, and 30 days post-transfection FACS was performed on each sample.
Twenty thousand cells were counted, checking for the expression of GFP. The data were then
analyzed using the WinMDI computer program.
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CHAPTER 5
RESULTS HYPOTHESIS 2

Construction of Hygromycin Resistant EGFP/RRE Expression Plasmids
Previous studies in the lab showed that visna RRE could inhibit Rev activity in
cotransfections; however, it was not total inhibition. We hypothesized that we could increase the
effectiveness of inhibition by adding a protein encoding ORF to the RNA, which has been shown
to stabilize mRNAs (Ross 1995). The first thing we did was to construct the new plasmids seen
in Figure 15. The plasmid pHygEGFP (Clontech) was digested with Hind III and Sal I to obtain
a 2.1 kb fragment that contained the ORF encoding a fusion between the hygromycin resistance
gene and the enhanced green fluorescent protein (EGFP). This fragment was isolated as
described and ligated into the vector pCMVlink that had been cut with Hind III and Sal I to
produce the plasmid pCMVlink-HygEGFP. The plasmids pCMVlink-RRE-V 7923-8124 (RRE-V),
pCMVlink-RRE-V 8001-8202 (RNA-V) and pCMVlink-RRE-C #28 were cut with Sal I and Sma I
to remove the RRE-V, RNA-V or RRE-C fragments. These fragments were then inserted into
the newly created plasmid pCMVlink-HygEGFP using the Sal I and Sma I sites. This produced
plasmids which encode hygromycin resistance, EGFP and contain RRE decoys on a single
mRNA. Each plasmid made was always checked to ensure quality and correct sizing by
restriction digest analysis and DNA sequencing.
Development of Hygromycin Resistant/RRE Expressing Cell Lines
Cotransfections were done in triplicate with the Hyg-EGFP/RRE-V expression plasmids
(pCMVlink-HygEGFP) and the Rev-V reporter plasmid, pEnv/L(+) to determine if the
overexpression of exogenous RRE would decrease Env expression from pEnv/L(+). As controls,
we repeated the previous cotransfections that had been shown to decrease Rev and Env
expression. None of the cotransfections were able to inhibit Rev or Env expression (data not
shown) contradicting the previous observations. Because the cotransfection of plasmids did not
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produce expected results, we decided to try another approach and make cell lines using the
hygromycin resistant/RRE expression plasmids (pCMVlink-Hyg EGFP, pCMVlink-Hyg EGFP
RRE-V, pCMVlink-Hyg EGFP RNA-V, and pCMVlink-Hyg EGFP RRE-C). Decoy expressing
cell lines would then be transfected with the pEnv/L(+) and pEnv1772 indicator constructs. Cos-1
cells were transfected using the Lipofectin/OPTI-MEM 1 method into eight 60mm plates. The
cells were cultured over time using media spiked with 250ug/ml Hygromycin. Once hygromycin
resistant cells were obtained and the non-plasmid containing cells were eliminated, the cells from
each separate transfection were combined into T175 flasks and cultured. The cell lines were then
checked by performing FACS to ensure that the cells actually did express the EGFP marker;
untransfected Cos-1 cells were used as the mock (Figure 16). The FACS analysis shows that all
four plasmid-containing cell lines (Hyg EGFP, Hyg EGFP RRE-V, Hyg EGFP RNA-V and Hyg
EGFP RRE-C) all express EGFP similarly, in terms of both percentage of cells that express and
in intensity. These results indicate that each cell line expresses similar quantities of the decoy
mRNA.
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Figure 15. Diagram of Plasmids Used to Make Hygromycin Resistant, EGFP-RRE Expressing
Cell Lines. The Hygromycin resistant gene and the EGFP gene are removed from the
pHygEGFP plasmid using Sal I and Hind III. The fragment was ligated to the pCMVlink
plasmid previously cut with Sal I and Hind III. RRE-V was removed from pCMVlink-RREV7923-8124 using Sal I and Sma I and then inserted into the new pCMVlink-HygEGFP plasmid to
make the plasmid pCMVlink-HygEGFP-RRE-V. The RNA-V and RRE-C plasmids were
constructed the same way.
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Figure 16. WinMDI Generated Graph Showing the Expression of EGFP from the RRE
Expressing Cell Lines. FACS was performed on each cell line (Cos-1 alone represented by the
red line, Hyg. alone represented by the black line, RRE-V represented by the blue line and RNAV indicated by the green line) using untransfected Cos-1 cells as the baseline to determine EGFP
expression.

Non-Significant Inhibition of Rev-V and Env-V Expression by Exogenous RRE-V in
Cotransfected Cells
Once the inhibitor expressing cell lines were established, we were able to proceed with
the transfections using the indicator constructs pEnv/L(+) and pEnv/Rev-V1772 (Figure 17) . Each
cell line was transfected with pEnv/L(+) and pEnv/Rev-V1772. Transfected cells were labeled
with 35S and harvested at the 24 and 48 hour time points. Immunoprecipations were then done to
determine the amount of Rev-V and Env-V expression resulting from each transfection and are
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shown in Figure 18. As expected, there was no Rev or Env expression in the 2 control lanes,
Cos-1 cells alone and pCMVlink-HygEGFP (no Rev present) cells alone (lanes 9 and 10). As
seen in the previous cotransfection, there was no significant difference in the amount of Rev or
Env expressed when the indicator constructs were transfected into the different cell lines. If the
RRE decoys had functioned as expected, then there should have been less Rev and Env
expressed in the RRE-V cell lines than in the hygromycin and RNA-V cell lines.
Phosphorimaging analysis was performed and the results from 3 independent experiments were
assayed (Figures 19 and 20). The 2 bar graphs show that there was no significant difference in
the amount of Rev or Env expressed in any of the cell lines.

Rev-V1514

Rev-V1772

Env-V1514

Env-V1772

CMV IE

CMV IE

Poly A

PENV/L(+)

Poly A

PENV/Rev-V1772

Figure 17. Indicator Constructs Used in CoTransfections. Both plasmids have a CMV IE
(Cytomegalovirus Immediate Early Promoter) that drives their transcription. pEnv/L(+)
expresses both Rev-V and Env-V from Visna Virus strain 1514. pEnv/Rev-V1772 expresses both
Rev-V and Env-V from Visna Virus strain 1772.
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Figure 18. SDS PAGE Gel of Transfections into RRE Expressing Cell Lines. The cell lines are
indicated above each lane. Lanes 2-4 were cotransfected with 2 ug pEnv/L(+) and lanes 5-7
were cotransfected with 2 ug pEnv/Rev-V1772. All samples were 35S labeled and coimmunoprecipitated for both Rev-V and Env-V. Lane 1 is the 14C molecular weight standard
with the sizes (kd) indicated on the left. Lane 9 is the mock transfection (no DNA added). Lane
10 is also a mock (pCMVlink-Hyg EGFP cell line alone, no DNA added). Hyg represents the
pCMVlink-Hyg EGFP cell line, RRE-V represents the pCMVlink-Hyg EGFP-RRE-V cell line
and RNA-V represents the pCMVlink-Hyg EGFP-RNA-V cell line. The locations of Rev-V and
Env-V are indicated on the right.
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Figure 19. Phosphorimager Analysis of Rev-V Expression in Transfected Cell Lines. The
columns indicate the average intensity of the Rev-V bands on SDS PAGE gels from each of the
3 experiments. The bars indicate the standard deviation of each average. pEnv represents
pEnv/L(+), p1772 represents pEnv/Rev-V1772, Hyg represents the pCMVlink-Hyg EGFP cell
line, RRE-V represents the pCMVlink-Hyg EGFP-RRE-V cell line and RNA-V represents the
pCMVlink-Hyg EGFP-RNA-V cell line.
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Figure 20. Phosphorimager Analysis of Env-V Expression in Transfected Cell Lines. The
columns indicate the average intensity of the Rev-V bands on SDS PAGE gels from each of the
three experiments. The bars indicate the standard deviation of each average. pEnv represents
pEnv/L(+), p1772 represents pEnv/Rev-V1772, Hyg represents the pCMVlink-Hyg EGFP cell
line, RRE-V represents the pCMVlink-Hyg EGFP-RRE-V cell line and RNA-V represents the
pCMVlink-Hyg EGFP-RNA-V cell line.

54

CHAPTER 6
RESULTS HYPOTHESIS 3

Evolution of a RRE-V RNA Aptamer
Several studies have shown that SELEX (Systematic Evolution of Ligands by
Exponential Enrichment) can be used to generate aptamers that can bind to HIV-1 Rev at least
ten times better than the RRE (Giver et al. 1993a, Giver et al. 1993b, Jensen et al. 1994, Jensen
et al. 1995). We, therefore, hypothesized that we could use this same process to evolve aptamers
that could bind to Rev-V more tightly than the RRE-V. It is also likely that such aptamers would
be more efficient Rev decoys. To see if we could make a better “binder” RRE-V for Rev-V a
“SELEX” oligo had to be made. This was a 60 nucleotide oligo with a T7 promoter sequence on
the 5’ end, a SP6 promoter sequence on the 3’ end and a 30 nt. random sequence in the middle.
The oligo was PCR amplified using the T7 and SP6 promoters and the resultant DNA was then
in vitro transcribed, resulting in a pool of RNAs that had known terminal sequences and random
interior sequences. This pool of RNAs was used to start the 9 rounds of SELEX. One round
consisted of in vitro transcription of DNAs to make RNAs that were then bound to GST Rev-V
and/or GST cell lysates to select out Rev binders. The resulting aptamers were then reverse
transcribed to make cDNAs. The cDNAs were then PCR amplified and used to start the next
round of SELEX.
Once 9 rounds of SELEX were completed, RNA binding assays were performed with a
32

P labeled RNA sample from the end of each round. The binding assays were performed using

both GST and GST-REV-V proteins. There should not be any binding of the RNA aptamers to
the GST protein because it does not contain any Rev sequences. We expected to see increased
binding over each round of the SELEX RNA aptamers to the GST-Rev-V protein because each
round of SELEX should eliminate the non-binding or weaker binding RRE-V aptamers, while
maintaining and developing stronger binders. Figure 21A demonstrates that the SELEX
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generated aptamers did not bind GST. The data presented in Figure 21B seem to indicate that we
successfully produced aptamers that specifically bind GST-Rev-V. However, there does not
appear to be a clear evolution of a better binding RRE-V ligand through the 9 rounds of SELEX
as indicated by the fact that the signal intensity does not increase in later rounds (Figure 21B,
lane 13).
It did not appear that there was an evolution of a better binding RRE-V ligand through 9
rounds of SELEX. Therefore, we decided to test 1 “round” of the SELEX ligands to see if it
could out-compete wildtype RRE-V for binding to Rev-V. We chose the ligand from round 6
because it seemed to be the best binder to Rev-V in the binding assay (Figure 21B, lane 7). We
synthesized 32P labeled RNA aptamer from round 6 as well as wildtype RRE-V and then
competed them against unlabeled wildtype RRE-V and RNA-V for binding to the GST-Rev-V
protein. Figure 22A shows the results when labeled wildtype RRE-V is competed against
increasing 5 fold serial dilutions of unlabeled RRE-V. The more diluted the unlabeled
competitor becomes, the more the labeled ligand is bound by the Rev protein. Figure 22B shows
the results of labeled RRE-V competed against increasing dilutions of unlabeled RNA-V. The
labeled RRE-V would be expected to “out-compete” the unlabeled RNA-V ligand for binding to
Rev-V because RNA-V does not specifically bind Rev. Labeled RRE-V does out-compete
unlabeled RNA-V for binding to Rev-V in all cases except for in lane 7. The decrease in RRE-V
binding observed in this lane is probably due a gel loading error. Figure 23A shows the results
when the labeled round 6 ligand is competed against increasing dilutions of unlabeled RRE-V.
In every case involving the unlabeled RRE-V as a competitor, there is little or no binding of the
labeled SELEX ligand to Rev-V. This suggests that the round 6 aptamer does not bind to Rev as
tightly as does the RRE-V. Figure 23B shows the results of the labeled round 6 ligand when
competed against increasing dilutions of unlabeled RNA-V. The labeled round 6 ligand was
able to out-compete unlabeled RNA-V for binding to Rev-V. These results indicate that we were
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able to produce a functional Rev-V binding aptamer by SELEX, but we were unable to produce a
better binder for Rev-V than wildtype RRE-V.
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Figure 21. 12% Urea/Polyacrylamide Gels of Binding Assays of the SELEX RNAs to GST and
GST-Rev-V. A.) RNAs labeled with 32P from rounds 2 through 9 of SELEX bound to GST
protein. B.) RNAs labeled with 32P from rounds 2 through 9 of SELEX bound to GST-Rev-V
cell lysate. Lane 1 is the Phi X174/Hinf1 marker with sizes indicated on the left. The locations
of the SELEX aptamer are indicated on the right. Lane 13 contains unbound 32P labeled wildtype
RRE-V.
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Figure 22. 6% Urea/Polyacrylamide Gels of the 32P Labeled Wildtype RRE-V Competition
Assays. A.) Competition Assay with unlabeled wildtype RRE-V. B.) Competition Assay with
unlabeled RNA-V. Lane 1 is the 10 bp molecular weight standard with the 100 bp location
indicated on the left. Lanes 2 through 7 contain the competition assays with 1:5 serial dilutions
of unlabeled wildtype RRE-V/RNA-V. Lane 8 had no unlabeled RRE-V/RNA-V added to the
reaction mix. Lane 10 contains an unbound labeled RRE-V. The amount of unlabeled RREV/RNA-V competitor is indicated above each lane. The location of RRE-V is indicated on the
right.
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Figure 23. 12% Urea/Polyacrylamide Gels of the 32P Labeled Round 6 SELEX Aptamer
Competition Assays. A.) Competition Assay with unlabeled wildtype RRE-V. B.) Competition
Assay with unlabeled RNA-V. Lane 1 is the 10 bp molecular weight standard with the 100 bp
location indicated on the left. Lanes 2 through 7 contains the competition assays with 1:5
dilutions of unlabeled wildtype RRE-V/RNA-V. Lane 8 had no unlabeled RRE-V/RNA-V
added to the reaction mix. Lane 10 contains an unbound labeled Round 6 ligand. The amount of
unlabeled RRE-V/RNA-V competitor is indicated above each lane. The location of the Round 6
RRE-V ligand is indicated on the right.
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CHAPTER 7
RESULTS HYPOTHESIS 4

Rev-C Trans-activation of RRE-V
Previous studies indicated that lentiviral Rev proteins can cross-activate. In particular,
our lab has shown in preliminary experiments that CAEV Rev can trans-activate thru the Visna
Virus RRE, albeit at a reduced efficiency (Hansen 2001). To quantify the degree to which RevC can trans-activate through the RRE-V, we performed multiple cotransfections with the
reporter plasmid pEnv/L(-) and the effector constructs pCMVlink, pCMVRev-V and pCMVRevC seen in Figure 24. The transfections were repeated 4 times using the Trans-IT LT1method
with a 1:4 ratio of effector plasmid to reporter plasmid. The cells were labeled with 35S and
harvested at 48 hours post-transfection. The cell lysates were then immunoprecipitated for Env
(Env-V), Rev-V and Rev-C. The results of a representative experiment are seen in Figure 25. No
Env is observed in Figure 25A lanes 2 and 3 which contain the mock (pTracer + pCMVlink) and
the negative control (pEnv/L(-) + pCMVlink). Neither of those transfections contain Rev
sequences and, therefore, should not express Env. As expected, lane 4 reveals a strong Env band
as a result of the transfection of pEnv/L(-) + pCMVRev-V and in lane 5 (Figure 25A) there is a
very faint Env band as the result of the transfection pEnv/L(-) + pCMVRev-C.
Figure 25B shows the results of the Rev immunoprecipitations. The two mock
transfections (pTracer + pCMVlink and pEnv/L(-) + pCMVlink) did not produce either a Rev-V
(lanes 3 and 5) or a Rev-C (lanes 4 and 6) band as expected. Lane 7 contains a Rev-V band as
expected when pEnv/L(-) was transfected with pCMVRev-V and lane 8 contains a Rev-C band
as expected when pEnv/L(-) was transfected with pCMVRev-C. The Rev-C band was less
intense than the Rev-V band indicating that Rev-C was less well expressed. The gels were
quanititated using phosporimager analysis to determine the amounts of Rev and Env expressed
and the results can be seen in Figure 26. The amount of Env-V was normalized to the amount of
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Rev present in each lane. Rev values were first adjusted according to the number of methionines
found in Rev-V (8) and Rev-C (5). The normalized Env expression trans-activated by either
Rev-V or Rev-C in 3 independent experiments is shown in Figure 26. In all 3 cases, Rev-C
trans-activated thru the RRE-V less well than did Rev-V.

CMV IE

Rev-V

Poly A

Poly A

CMV IE

PCMVRev-V

PCMVlink

Rev-V1514
Env-V1514

Rev-C
CMV IE

CMV IE

Poly A

PCMVRev-C

Poly A
STOP

PENV/L(-)

Figure 24. Plasmids Used in Rev-C Cross-activation Study. The 3 effector constructs used are:
pCMVlink, pCMVRev-V and pCMVRev-C and pEnv/L(-) is the indicator construct. All four
plasmids have a CMV IE (Cytomegalovirus Immediate Early Promoter) that drives their
transcription. pCMVlink is a high-level expression plasmid (it does not contain any Rev or Env
sequences). pCMVRev-V expresses the Visna Virus Rev protein. pCMVRev-C expresses
CAEV Rev protein. pEnv/L(-) expresses both Rev-V and Env-V from Visna Virus strain 1514.
It has a termination codon located in the second Rev ORF which produces a truncated, nonfunctional Rev protein and only expresses Env protein if Rev is provided in trans.
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Figure 25. SDS PAGE Gels of Env and Rev Immunoprecipitations. Cos-1 cells were
transfected (1:4 ratio) with a reporter construct (pEnv/L(-)) and an effector construct. The DNA
cotransfection mixes are indicated above each lane. The cells were then 35S labeled and
immunoprecipitated for Env and either Rev-V or Rev-C. A.) 10% SDS PAGE from Env
immunoprecipitations. B.) 15% SDS PAGE from Rev-V and Rev-C immunoprecipitations.
Lane 1 is the 14C molecular weight standard with the sizes (kDal) indicated on the left. The
pTracer + pCMVlink transfection is the mock transfection and the pEnv/L(-) + pCMVlink is the
negative control. Link represents pCMVlink, Rev-V represents pCMVRev-V and Rev-C
represents pCMVRev-C. The Env sample was immunoprecipitated with either anti-Env and the
Rev samples were immunoprecipitated with anti-Rev-V and anti-Rev-C (indicated above each
lane). The locations of Env, Rev-V and Rev-C are indicated on the right.
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Figure 26. Phosporimager Analysis of Env Expression. The columns indicate the percent of
Env expression from the cotransfections. The percent of Env expression was calculated by
normalizing the Rev values according to the number of methionines in each. Each Env value
was then normalized to the amount of Rev present. Rev-V directed Env expression was set at
100% and the Rev-C driven expression was calculated by dividing the normalized Env-C value
by the Env-V value and multiplying by 100. The blue columns represent Rev-V trans-activation
and the red columns represent Rev-C trans-activation.
After showing that Rev-C could trans-activate RRE-V but at a lower efficiency than RevV, we decided to see if the reason it did not trans-activate the RRE-V as well was because Rev-C
does not bind RRE-V as well as Rev-V can. To study this question, we did RNA binding assays
using Rev-C proteins and various RREs that were labeled with 32P. After making the Rev-C
proteins using in vitro translations, we electrophoresed them on a SDS PAGE gel to ensure they
were the correct size and expressing Rev-C (+ only) (data not shown). We then in vitro
transcribed RRE-V, RRE-C (+), RRE-C (-) and RNA-V RNA in the presence of

32

P rUTP.

Those probes were checked for quality as well by running them out on a 6% urea/polyacrylamide
gel (data not shown). The binding assays were performed as described previously and the results
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are shown in Figure 27. Lane 2 containing Rev-C(+) + RRE-C (+) gives the expected results
with a high intensity band indicating the presence of RRE-C. Lane 3 containing Rev-C (+) +
RRE-V shows a very light band indicating the presence of RRE-V. Lanes 4 and 5 contain the
negative control binding assays (Rev-C(+) + RRE-C(-) and Rev-C(+) + RNA-V) and do not
show any Rev bands. These results were phosphorimager analyzed and resulted in a bar graph
depicting the difference in (percentage) binding that Rev-C had to RRE-C and RRE-V. Figure
28 indicates that Rev-C binds RRE-V less than 7% as well as it binds to RRE-C.
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Figure 27. Representative 6% Urea/Polyacrylamide Gel of RNA Binding Assays. 35S labeled
Rev-C (+ and -) IVT proteins were bound to a 32P labeled RRE (either RRE-C(+), RRE-C(-),
RRE-V or RNA-V). RRE-C transfections were immunoprecipitated with anti Rev-C and the
RRE-V/RNA-V transfections were immunoprecipitated with anti Rev-V. Lane 1 is the 32P
labeled 100 bp molecular weight standard with the sizes indicated on the left. The locations of
Rev-V and Rev-C are indicated on the right.
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Figure 28. Phosporimager Analysis of Rev-C Binding to RRE-V and RRE-C. The columns
indicate the percent of Rev-C binding to RRE-V and RRE-C from the RNA binding assays. The
percent of Rev-C binding was calculated by dividing the RRE-C values by the RRE-V values
and multiplying by 100. RRE-C binding by Rev-C was set at 100% and RRE-V binding by RevC was calculatd as stated earlier. The red columns represent RRE-C and the blue columns
represent RRE-V.
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CHAPTER 8
DISCUSSION

Hypothesis 1
FACS Analysis of Cells Expressing Rev-C
Based on the graphical analysis (Figure 14) of Cos-1 cells transfected with Rev-C
expression plasmids, it can be concluded that Rev-C is not acutely toxic to cells. There was not a
significant difference in the how quickly the Rev/GFP transfected cells died. Over the 30-day
time period, none of the transfected cells were able to maintain a higher level of GFP expression
over the other transfected cells. If Rev had been acutely toxic to cells, we would have expected
the number of Rev-C/GFP transfected cells to decrease more rapidly compared to the pTracer
alone transfected cells. From these results, we were able to conclude that Rev may be toxic to
cells, it just is not acutely toxic. The previous experiment that indicated the basic domain of Rev
might be toxic was done over a longer period of time than our experiment was done. Those cells
were transfected and G418 selected for a long period of time. We did not use antibiotic selection
on our transfected cells. However, we did lose some transfected cells each time we split and refed them, but the loss of transfected cells should have been relatively equal for the different
DNAs. Thus, Rev may be toxic to cells over time, but it is not acutely toxic and therefore it
would not be a good way to control lentiviral replication by overexpressing the basic domain of
Rev.

Hypothesis 2
Development of Hygromycin Resistant/RRE Expressing Cell Lines
The results from cotransfections done with the new RRE-V expression plasmids
(pCMVlink-HygEGFP) and the Rev-V reporter plasmid (pEnv/l(+)) (data not shown) and also
the repeat cotransfections earlier were surprising in that none of them seemed to inhibit Rev or
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Env expression. Those results contradicted previous experimental results that had indicated
RRE-V would inhibit Rev and Env expression by acting as a decoy for Rev binding. As a result
we decided upon an alternate approach; to develop hygromycin resistant/EGFP and RRE
expressing cell lines. Before each transfection into Cos-1 cells, the plasmids were checked for
identity. Once the cell lines were established, we performed FACS analysis to ensure that the
cell lines were expressing GFP. As can be seen in Figure 16, all 3 cell lines were expressing
GFP and are doing so at similar levels validating the results of the immunoprecipitations seen in
Figures 17, 18, and 19. Because they were expressing GFP at approximately the same amount,
Rev and Env protein expression after transfections with pEnv/L(+) and pEnv1772 are considered
equal and the results from the different cell lines can be compared as such.
The data from the cell line transfection experiments (Figures 18, 19, and 20) indicate that
the new hygromycin resistant/EGFP-RRE expression constructs do not inhibit Env expression
and hence, Rev activity. We had hypothesized that the new hygromycin resistant constructs
would actually be better inhibitors of Rev than the link + RRE-V constructs. They were
designed to produce a more stable decoy mRNA. There was no significant inhibition of Rev or
Env in any of the transfections (Figure 18, lanes 2-7). Because the 2 control lanes (Figure 18,
lanes 9 and 10) gave the expected results of no Rev or Env expression we know that the Cos-1
cells were not contaminated and the pCMVlink-Hyg-EGFP cell lines are also not contamintated
with Rev or Env. We had hypothesized that the RRE cell lines would express less Rev and Env
than the hygromycin or the RNA cell lines because the expressed RREs would act as decoys and
bind Rev. However, this was not the case. The phosporimager analysis of both Rev and Env
expression in Figures 19 and 20 further confirm the that there was no significant inhibition of
Rev or Env expression when RRE-V expressing cell lines were transfected with plasmids
expressing both Rev and Env. The new hygromycin/RRE constructs may not have worked for
several reasons. First, exogenous RREs may not be able to act as decoys and bind Rev as
previously thought, but that is unlikely to be correct based on published data in other lentiviral
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systems. We believe the hygromycin insert may be binding to and forming a secondary structure
with the RRE, which is preventing it’s binding to Rev. Another plausible explanation is that the
decoy RNAs may be translating so well that the ribosomes are occluding the RRE, thus
preventing it from binding Rev.

Hypothesis 3
Evolution of a RRE-V RNA Aptamer
Based on published data we hypothesized that we could produce aptamers that could bind
Rev-V more tightly than RRE-V using SELEX. We first made an oligo we believed would give
us the best chance at producing a “tight binding” RRE-V. We then used the resulting aptamers
from SELEX to perform RNA binding assays (Figures 20 A & B) with GST and GST-Rev-V
which produced both promising and distressing results. It is apparent from Figure 20A that we
were successful in producing a selective binder because none of the aptamers bound to GST. At
first glance the results seen in Figure 20B were also very promising. It indicated that we were
able to produce a RRE aptamer that would bind GST-Rev-V. However, we expected to see an
increase in the binding of Rev by the aptamers as more rounds of SELEX were completed. That
would have indicated that we were able to amplify a very tight binding aptamer. However, it
appears that we were unable to selectively amplify 1 or several tight binders over time.
In order to determine whether our SELEX aptamer would out-compete wildtype RRE-V
for binding to Rev-V, we performed competition assays. Figure 21A gave us the expected
results showing the labeled RRE-V was able to out-compete the unlabeled RRE-V competitor as
it is diluted. Figure 21B is the positive control for this experiment. The unlabeled competitor is
RNA-V, which is the “non-binding” RRE. It does not bind Rev-V and thus in all cases the
labeled RRE-V should out-compete it. Other than lane 7, it gave the expected results. The
absence of a band in lane 7 is probably due to a loading error. If our aptamer was a better binder
to Rev-V than wildtype RRE-V then, the results in Figure 22A would have been much different.
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We had predicted that our aptamer would out-compete the unlabeled RRE-V, but in all cases the
unlabeled wildtype competitor was the better binder. The absence of a band in lane 8 is difficult
to explain, however. There was no competitor added to that reaction, so there should have been
a band present. Figure 22B again backs up our statement that we were able to make a RNA
ligand that binds Rev-V. In all of the reactions using RNA-V as the unlabeled competitor, our
aptamer was able to out-compete it for binding to Rev-V. Thus, while we were able to produce a
functional RRE-V aptamer from SELEX we were not able to produce a better binding RRE-V
that could be used as a decoy.
There are several possible reasons why we were unable to produce a better binding RRE.
First, we may not have done enough rounds of SELEX. Perhaps if we had continued with more
rounds, then we might have been able to evolve a better binder. However, we do not believe that
would happen. It is very possible that the “better binder” we are seeking is not in our library.
Perhaps if we just re-initiate transcription at the beginning and start with a new library we may
include a better binder or if we make a different oligo with a larger unknown sequence it would
enable us to broaden our library and encompass a better binder.

Hypothesis 4
Rev-C trans-activation of RRE-V
Numerous reports have shown that lentiviruses can trans-activate across species.
Experiments in our lab have suggested that Rev-V can trans-activate thru the RRE-C but at
lower levels than it does RRE-V. This led us to hypothesize that Rev-C can cross-activate RREV but at a lower efficiency than it can RRE-C. We initially did cotransfections assays to
determine if Rev-C can in fact trans-activate RRE-V. Based on the results seen in Figures 25A
and B, we were able to conclude that Rev-C can trans-activate thru the RRE-V. As expected in
Figure 25A, the two control transfections did not produce an Env-V band validating our
experimental data from this gel. It is evident from this gel that Rev-C does not trans-activate
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through the RRE-V as well as Rev-V based on the intensities of the Env bands in lanes 4 and 5.
In the Rev gel (Figure 25B), the Rev-C band is also not as dark as the Rev-V band which is
comparable to the results seen in Figure 25A. Quantitations done from the results of these 2 gels
(Figure 26) show that on average Rev-C trans-activates through the RRE-V at 19.7% the amount
observed with Rev-V. Our hypothesis that Rev-C does not trans-activate RRE-V as well as RevV because it does not bind as well, was supported by the results seen in Figures 27 and 28. The
RNA binding assays confirm that Rev-C does not bind RRE-V as well as it can bind RRE-C
(Figure 27, lanes 2 and 3). In fact it binds RRE-V at only 5.2% the efficiency that it binds its
own RRE (Figure 28). Based on all of these results, we can state that Rev-C can trans-activate
RRE-V but at a lower capacity than RRE-C because Rev-C binds the RRE-V less efficiently than
does the wildtype Rev protein.
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APPENDIX

Table 2. List of Abbreviations Used

AIDS

-Acquired Immune Deficiency Syndrome

APS

-ammonium persulfate

bp

-base pairs

CA

-major capsid protein

CAEV

-Caprine Arthritis Encephalitis Virus

cpm

-counts per minute

CMV IE

-Cytomegalovirus immediate early promoter

CO2

-carbon dioxide

CSA

-casamino acids

C-terminal

-carboxy terminal

dATP

-deoxyadenosine triphosphate

ddH20

-double distilled water

DEPC

-diethylpyrocarbonate

DMEM

-Dulbecco’s Minimal Essential Medium

DMSO

-dimethyl sulfoxide

DNA

-deoxyribonucleic acid

DS-DNA

-double stranded deoxyribonucleic acid

DTT

-DL-dithiothreitol

dTTP

-deoxythymidine triphosphate

dUTP

-deoxyuridine triphosphate

E. coli

-Escherichia coli bacteria

EDTA

-ethylenediaminetetraacetic acid
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Table 2 (continued)
EGFP

-enhanced green fluorescent protein

EIAV

-Equine Infectious Anemia Virus

eIF-5A

eukaryotic initiation factor 5A

Env-V

-Visna Virus envelope protein

EtOH

-ethanol

FACS

-Fluorescence Activated Cell Sorter

FCS

-fetal calf serum

FIV

-Feline Immunodeficiency Virus

Gag

-group specific antigen

GFP

-green fluorescent protein

gp

-glycoprotein

GST

-glutathione-S-transferase

H202

-hydrogen peroxide

HIV-1

-Human Immunodeficiency Virus type 1

HTLV

-Human T cell Leukemia Virus

Hyg

-hygromycin

IP

-immunoprecipitation

IPTG

-isopropyl-ß-D-thiogalactopyranoside

kDal

-kilodaltons

M

-Molar

MA

-matrix protein

MEM

-Earles’ Minimal Essential Medium

mg

-milligram

MgCl2

-magnesium chloride

ml

-milliliter
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Table 2 (continued)
mM

-millimolar

MnCl2

-manganese chloride

MOPS

-3-(N-morproline) propane sulfonic acid

mRNA

-messenger ribonucleic acid

NaCl

-sodium chloride

NaOAc

-sodium acetate

NaOH

-sodium hydroxide

NC

-nucleocapsid protein

NES

-nuclear export signal

NLS

-nuclear localization signal

NPC

-nuclear pore complex

OD

-optical density

oligo

-oligonucleotide

ORF

-open reading frame

PAGE

-polyacrylamide gel electrophoresis

PBS

-phosphate buffered saline

PCR

-polymerase chain reaction

PEG

-polyethylene glycol

Rev-C

-Caprine Arthritis Encephalitis Virus Rev protein

Rev-V

-Visna Virus Rev Protein

RNA

-ribonucleic acid

RRE-C

-Caprine Arthritis Encephalitis Virus Rev Response Element

RRE-V

-Visna Virus Rev Response Element

RT

-reverse transcriptase

RT°

-room temperature
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Table 2 (continued)
SDS

-sodium dodecyl sulfate

SELEX

-Systematic Evolution of Ligands by Exponential Enrichment

SIV

-Simian Immunodeficiency Virus

SV40

-Simian Virus 40

TAE

-Tris-acetate-EDTA buffer

TBE

-Tris-borate-EDTA buffer

TBS

-Tris buffered saline

TCA

-trichloroacetic acid

TE

-Tris-EDTA buffer

tRNA

-transfer ribonucleic acid

uCi

-microcurie

ug

-microgram

ul

-microliter

UV

-ultraviolet
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